Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Norihito Shibata(National Institute of Health Sciences), Mikihiko Naito(Meiji Pharmaceutical University)
Cited by 51
Related Papers
Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses
|Cell|2012|598
Critical role of mitochondrial ubiquitination and the OPTN–ATG9A axis in mitophagy
|The Journal of Cell Biology|2020|206
Development of hybrid small molecules that induce degradation of estrogen receptor‐alpha and necrotic cell death in breast cancer cells
|Cancer Science|2013|128
Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation
|Journal of Biological Chemistry|2018|103
Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway
|Cell Death and Disease|2014|99